Karyopharm Therapeutics
KPTI
71 hedge funds and large institutions have $587M invested in Karyopharm Therapeutics in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 22 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less call options, than puts
Call options by funds: $1.99M | Put options by funds: $2.21M
9% less funds holding
Funds holding: 78 → 71 (-7)
17% less capital invested
Capital invested by funds: $704M → $587M (-$117M)
32% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$17.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.9M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$8.27M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$6.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$11.3M |
| 2 |
VAM
Visium Asset Management
New York
|
-$6.98M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.49M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.97M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.13M |
KPTI Hedge Fund Activity: Q3 2014 in Review
71 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2014, worth a combined $587M — down 17% from $704M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of KPTI and 15 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 33 added.
The largest buyer was Fidelity Investments, adding an estimated $24.3M. The largest seller was Foresite Capital Management I, cutting an estimated $11.3M.
- 71 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2014, down from 78 in Q2 2014.
- Funds reported $587M of Karyopharm Therapeutics stock for Q3 2014, down 17% quarter-over-quarter.
- 15 funds opened new Karyopharm Therapeutics positions in Q3 2014 and 22 closed out, a net change of -7 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2014 was Fidelity Investments, an estimated $24.3M added.
- The largest Karyopharm Therapeutics seller in Q3 2014 was Foresite Capital Management I, an estimated $11.3M sold.
Based on aggregated 13F filings for Q3 2014.